Basilea presents new research data on a biomarker for its novel oncology drug candidate BAL101553 at AACR – Market Wire

broad-spectrum cephalosporin antibiotic, for the first-line treatment of potentially life-threatening resistant bacterial infections. Ceftobiprole has a broad coverage of both Gram- positive bacteria, including MRSA, and many clinically important Gram …

Leave a Reply

Your email address will not be published.